Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Leptin in the Maintenance of Reduced Body Weight

This study is ongoing, but not recruiting participants.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Beth Israel Deaconess Medical Center Identifier:
First received: June 16, 2010
Last updated: December 17, 2015
Last verified: December 2015
You are invited to take part in a research study about the role of leptin (a fat cell hormone that normally circulates in the blood) on maintaining a reduced body weight. This study will also evaluate how leptin impacts hormone levels, metabolic rate (how many calories are used at rest), autonomic nervous function (the part of your brain that controls your heart rate and breathing), changes in body composition and your sense of appetite. Under normal conditions, leptin is secreted by fat cells and signals to the brain to decrease appetite and regulate energy usage and hormone levels. When obese individuals lose weight, their leptin levels go down, which may cause them to later regain the weight. This study will provide leptin as an investigational medication (not yet approved by the Food and Drug Administration) to increase the levels of the leptin hormone that normally circulates in your blood back to a normal range. We will see if this can help you to maintain your reduced body weight and improve your hormonal and metabolic function.

Condition Intervention Phase
Drug: Leptin
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Leptin in the Maintenance of Reduced Body Weight

Resource links provided by NLM:

Further study details as provided by Beth Israel Deaconess Medical Center:

Primary Outcome Measures:
  • Body Weight [ Time Frame: 6 months after randomization ] [ Designated as safety issue: No ]

Estimated Enrollment: 90
Study Start Date: July 2008
Estimated Study Completion Date: December 2015
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Leptin Drug: Leptin
Hormone - daily self injections for 6 months
Placebo Comparator: Placebo Drug: Placebo


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria for dietary induced weight loss group:

  • Age 18 or older
  • Body mass index (pre weight loss) between 30 and 40 kg/m2.
  • Weight loss achieved over a period not greater than 6 months.

Exclusion criteria for dietary induced weight loss group:

  • Use of a very low calorie diet in the year prior to the start of the study
  • History of diabetes
  • History of any illness that may affect the concentrations of the hormones to be studied (such as anemia, infectious diseases, renal or hepatic failure, cancer, lymphoma, clinically evident hypogonadism, malabsorption or malnourishment, hypo or hyperthyroidism, hypercortisolism, alcoholism or drug abuse, eating disorders)
  • On medications known to affect the hormones to be measured in this study (such as glucocorticoids, anti seizure medications or thyroid hormones), or medications for weight loss.
  • Known history of reactions or known hypersensitivity to E. Coli derived proteins
  • Breast feeding, pregnant, or wanting to become pregnant during the next year
  • Subjects with any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g. cochlear implants, pacemakers, neuron or biostimulators, electronic infusion pumps, etc.).
  • Subjects with any type of ferromagnetic bioimplant that could potentially be displaced or damaged, such as aneurysm clips, metallic skull plates, etc.
  • Subjects that exhibit noticeable anxiety and/or claustrophobia.
  • Subjects who have cardiac or known circulatory impairment, and/or the inability to perspire (poor thermoregulatory function).
  • Subjects who have significant sensory or motor impairment; - Subjects who suffer from epilepsy, in particular photo-sensitive epilepsy (this would be a risk for scanning with visual stimulation).
  • Subjects with neurological problems that might interfere or complicate testing (e.g. presence of titubation).
  • Subjects who cannot adhere to the experimental protocol for any reason.

Inclusion criteria for lap band surgery induced weight loss group:

  • Age 18 or older.
  • Body mass index (pre weight loss) between 30 and 40 kg/m2.
  • Weight loss achieved over a period not greater than 6 months.
  • Approved for bariatric surgery as per BIDMC Bariatric Clinic guidelines
  • Adult men and women, age 18-65
  • English speaking
  • Willing and able to take part in a multi year study involving visits and telephone interviews
  • Enrolled prior to bariatric surgery.

Exclusion Criteria:

  • Any condition that would exclude a patient from lap band surgery as listed below -
  • patients with untreated major depression or psychosis
  • binge eating disorders
  • current drug and alcohol abuse
  • severe cardiac disease with prohibitive anesthetic risks
  • severe coagulopathy i
  • inability to comply with nutritional requirements including life-long vitamin replacement.
  • pregnancy
  • Any additional condition which is not in accordance with standard of care as per Bariatric Clinic at BIDMC.
  • Any condition which in the opinion of the investigators makes the candidate unsuitable for participation in this study
  • Diabetes controlled by medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01155180

United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigator: Christos S Mantzoros, MD Beth Israel Deaconess Medical Center
  More Information

Responsible Party: Beth Israel Deaconess Medical Center Identifier: NCT01155180     History of Changes
Other Study ID Numbers: 2008-P000190  R01DK079929 
Study First Received: June 16, 2010
Last Updated: December 17, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Body Weight
Signs and Symptoms processed this record on January 17, 2017